NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
2.03
Dollar change
-0.02
Percentage change
-0.98
%
Index- P/E- EPS (ttm)-1.60 Insider Own23.70% Shs Outstand7.02M Perf Week1.50%
Market Cap14.26M Forward P/E- EPS next Y-2.04 Insider Trans0.00% Shs Float5.36M Perf Month2.01%
Enterprise Value9.55M PEG- EPS next Q-0.26 Inst Own40.19% Short Float0.54% Perf Quarter-18.80%
Income-5.84M P/S- EPS this Y36.96% Inst Trans2.37% Short Ratio1.51 Perf Half Y16.00%
Sales0.00M P/B2.24 EPS next Y-67.67% ROA-50.92% Short Interest0.03M Perf YTD20.83%
Book/sh0.90 P/C1.03 EPS next 5Y0.61% ROE-58.78% 52W High5.59 -63.69% Perf Year-53.03%
Cash/sh1.98 P/FCF- EPS past 3/5Y-20.43% -21.29% ROIC-37.57% 52W Low1.55 30.97% Perf 3Y-82.63%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility7.14% 5.85% Perf 5Y-94.82%
Dividend TTM- EV/Sales- EPS Y/Y TTM-23.23% Oper. Margin- ATR (14)0.12 Perf 10Y-99.90%
Dividend Ex-Date- Quick Ratio15.73 Sales Y/Y TTM- Profit Margin- RSI (14)51.49 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio15.73 EPS Q/Q48.58% SMA203.00% Beta0.39 Target Price10.33
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-2.84% Rel Volume0.39 Prev Close2.05
Employees16 LT Debt/Eq0.00 EarningsMay 14 AMC SMA200-18.86% Avg Volume19.14K Price2.03
IPOJun 21, 2010 Option/ShortNo / Yes EPS/Sales Surpr.28.57% - Trades Volume7,382 Change-0.98%
May-14-25 04:15PM
Apr-28-25 04:30PM
Apr-04-25 04:15PM
Feb-14-25 04:15PM
Feb-13-25 07:00AM
04:30PM Loading…
Dec-13-24 04:30PM
Oct-31-24 08:15AM
Oct-21-24 08:15AM
Aug-09-24 09:53PM
04:20PM
Jun-24-24 08:20AM
May-10-24 08:53PM
04:15PM
Apr-11-24 09:00AM
Apr-02-24 09:00AM
04:30PM Loading…
Mar-21-24 04:30PM
Mar-07-24 08:45AM
Mar-04-24 04:30PM
Feb-09-24 04:15PM
Jan-04-24 04:15PM
Dec-18-23 05:51AM
Dec-15-23 04:10PM
Nov-20-23 04:05PM
Oct-26-23 04:05PM
Oct-25-23 09:10AM
Oct-19-23 09:15AM
Oct-12-23 12:15PM
12:10PM
Oct-10-23 09:00AM
Sep-28-23 08:15AM
11:40AM Loading…
Aug-16-23 11:40AM
Aug-09-23 04:15PM
Aug-04-23 08:56AM
Jul-26-23 09:00AM
Jun-28-23 03:55PM
07:55AM
Jun-27-23 08:15AM
Jun-15-23 08:00AM
May-17-23 08:22AM
May-11-23 04:30PM
Apr-20-23 08:30AM
Apr-04-23 08:45AM
Mar-23-23 04:30PM
Mar-16-23 04:10PM
Mar-15-23 08:10AM
Feb-15-23 05:11AM
Feb-12-23 09:00AM
Feb-10-23 09:00AM
Feb-01-23 08:15AM
Jan-18-23 05:50AM
Jan-17-23 12:30PM
08:30AM
Dec-22-22 06:47AM
Dec-20-22 08:30AM
Dec-16-22 09:00AM
Dec-02-22 08:00AM
Nov-03-22 09:00AM
Oct-03-22 11:10AM
Sep-30-22 08:00AM
Sep-08-22 04:30PM
Sep-07-22 08:00AM
Aug-24-22 07:15AM
Aug-12-22 04:30PM
Aug-03-22 08:15AM
Jul-16-22 08:11AM
Jul-11-22 08:30AM
May-24-22 01:04PM
07:55AM
May-19-22 04:30PM
10:12AM
May-17-22 08:43AM
May-13-22 08:55AM
Apr-28-22 07:45AM
Mar-29-22 09:00AM
Mar-24-22 04:30PM
Mar-22-22 08:00AM
Feb-18-22 07:05AM
Feb-17-22 08:00AM
Feb-14-22 09:00AM
Feb-06-22 07:42AM
Jan-26-22 07:45AM
Jan-13-22 09:55AM
07:55AM
Jan-06-22 05:28AM
Dec-28-21 04:15PM
Dec-08-21 06:34AM
Dec-01-21 07:58AM
Nov-04-21 08:00AM
Oct-21-21 10:16AM
Oct-19-21 09:32AM
08:00AM
Oct-09-21 10:29AM
Sep-22-21 04:46AM
Sep-20-21 02:43PM
01:55PM
12:37PM
11:11AM
08:00AM
Sep-09-21 07:00AM
Sep-01-21 10:30AM
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), EB02 for hemorrhoids, and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.